Appln. No.: 10/572,671 Group Art Unit No.: 1624

Amendments to the Claims:

The listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claims 1-8 (Canceled).

9. (Previously presented): A compound of formula (I):

$$(R^2)_m$$
 $(CH_2)_p$
 $(R^3)_n$
 (I)

wherein:

R¹ represents hydrogen or methyl;

 R^2 represents hydrogen or methyl;

m represents 1;

R³ represents hydrogen, methyl or halogen;

R⁴ and R⁵ independently represent hydrogen or methyl;

n represents 1;

p represents 1 or 2;

J represents CH₂, CO, or O;

A represents phenyl optionally substituted by a halogen atom; or a pharmaceutically acceptable salt thereof, or a hydrate thereof.

10. (Previously presented): A compound which is:

3-[(3-Chlorophenyl)methyl]-8-(1-piperazinyl)quinoline;

(3-Chlorophenyl)[8-(1-piperazinyl)-3-quinolinyl]methanone;

Appln. No.: 10/572,671 Group Art Unit No.: 1624

3-(Phenyloxy)-8-(1-piperazinyl)quinoline;

or a pharmaceutically acceptable salt thereof, or a hydrate thereof.

11. (Previously presented): A pharmaceutical composition which comprises the compound, salt, or hydrate according to claim 9 and a pharmaceutically acceptable carrier or excipient.

- 12. (Previously presented): A pharmaceutical composition which comprises the compound, salt, or hydrate according to claim 10 and a pharmaceutically acceptable carrier or excipient.
- 13. (Previously presented): A method of treating a cognitive memory disorder which comprises administering a therapeutically effective amount of the compound, salt, or hydrate according to claim 9 to a patient in need thereof, wherein the cognitive memory disorder is selected from age related cognitive decline, mild cognitive impairment, and cognitive deficits in schizophrenia.
- 14. (Previously presented): A method of treating a cognitive memory disorder which comprises administering a therapeutically effective amount of the compound, salt, or hydrate according to claim 10 to a patient in need thereof, wherein the cognitive memory disorder is selected from age related cognitive decline, mild cognitive impairment, and cognitive deficits in schizophrenia.
- 15. (Previously presented): A method of treating depression or anxiety which comprises administering to a patient in need thereof a therapeutically effective amount of the compound, salt, or hydrate according to claim 9.
- 16. (Previously presented): A method of treating depression or anxiety which comprises administering to a patient in need thereof a therapeutically effective amount of the compound, salt, or hydrate according to claim 10.

Appln. No.: 10/572,671 Group Art Unit No.: 1624

- 17. (Previously presented): A method of treating obesity which comprises administering to a patient in need thereof a therapeutically effective amount of the compound, salt, or hydrate according to claim 9.
- 18. (Previously presented): A method of treating obesity which comprises administering to a patient in need thereof a therapeutically effective amount of the compound, salt, or hydrate according to claim 10.
- 19. (Currently amended): A method of <u>treating</u> Alzheimers disease which comprises administering to a patient in need thereof a therapeutically effective amount of the compound, salt, or hydrate according to claim 9.
- 20. (Previously presented): A method of treating Alzheimers disease which comprises administering to a patient in need thereof a therapeutically effective amount of the compound, salt, or hydrate according to claim 10.